The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Official Title: International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study)
Study ID: NCT02305654
Brief Summary: This is an international phase III trial, with a Bayesian design, incorporating two sequential randomisations. It efficiently examines a series of questions that routinely arise in the sequencing of treatment. The study design has evolved from lengthy international consultation that has enabled us to build consensus over which questions arise from current knowledge and practice. It will enable potential randomisation for the majority of patients with inguinal lymph node metastases and will provide data to inform future clinical decisions. InPACT-neoadjuvant patients are stratified by disease burden as assessed by radiological criteria. Treatment options are then defined according to the disease burden strata. Treatment is allocated by randomisation. Patients may be allocated to one of three initial treatments: A. standard surgery (ILND); B. neoadjuvant chemotherapy followed by standard surgery (ILND); or C. neoadjuvant chemoradiotherapy followed by standard surgery (ILND). After ILND, patients are defined as being at low or high risk of recurrence based on histological interpretation of the ILND specimen. Patients at high risk of relapse are eligible for InPACT-pelvis, where they are randomised to either: P. prophylactic PLND Q. no prophylactic PLND
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: MALE
Healthy Volunteers: No
Los Angeles County-USC Medical Center, Los Angeles, California, United States
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Moffitt Cancer Center, Tampa, Florida, United States
Grady Health System, Atlanta, Georgia, United States
Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States
Mayo Clinic, Rochester, Minnesota, United States
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, United States
Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
Velindre NHS Trust, Cardiff, , United Kingdom
University Hospitals of Leicester NHS Trust, Leicester, , United Kingdom
The Royal Marsden NHS Foundation Trust, London, , United Kingdom
St George's Hospital NHS Foundation Trust, London, , United Kingdom
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, , United Kingdom
Swansea Bay University Health Board, Swansea, , United Kingdom
Name: Steve Nicholson
Affiliation: Mid and South Essex NHS Foundation Trust
Role: STUDY_CHAIR
Name: Curtis Pettaway
Affiliation: University of Texas M.D. Anderson Cancer Center ; 713-792-3250 ; cpettawa@mdanderson.org
Role: STUDY_CHAIR